Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Somatostatinoma 2Neuroendocrine Tumors 2Vipoma 1Uveal Melanoma 1Small Cell Lung Carcinoma 1Pheochromocytoma 1Neuroblastoma 1Neoplasms 1Melanoma 1Medulloblastoma 1Lung Neoplasms 1Kidney Neoplasms 1Insulinoma 1Head and Neck Neoplasms 1Glucagonoma 1Gastrinoma 1Esthesioneuroblastoma, Olfactory 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1Adenoma, Islet Cell 1

Interventions

Cyclophosphamide 20Etoposide 19Temozolomide 16Carboplatin 16Filgrastim 15Vincristine 11Cisplatin 11Radiotherapy 10Thiotepa 9Melphalan 8Granulocyte Colony-Stimulating Factor 8etoposide phosphate 7Lomustine 7Peripheral Blood Stem Cell Transplantation 6Radiation 5Methotrexate 5Magnetic Resonance Spectroscopy 5Topotecan 4Mesna 4Gemcitabine 4Busulfan 4sargramostim 3gallium Ga 68 dotatate 3Thalidomide 3Stem Cell Transplantation 3Irinotecan 3Ifosfamide 3Donepezil 3Celecoxib 3Automobiles 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Medulloblastoma × pentetreotide × Clear all
NCT01869725 2021-09-22

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

University of Iowa

Phase 2 Completed
68 enrolled 8 charts
CNSEndocrineNET

Medulloblastoma, Neuroblastoma, Somatostatinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡